venBio
Jaume Pons is a seasoned professional in the biopharmaceutical industry with extensive experience in leadership roles. Currently, Pons serves as a Venture Partner at venBio since April 2015 and has been President and Chief Scientific Officer at ALX Oncology from April 2015 to April 2025, focusing on the development of innovative biologics for cancer immunotherapy. Previously, Pons held the position of President and CEO at Rinat, a company acquired by Pfizer, from October 2007 to February 2015, and also served as Senior Vice President and Chief Scientific Officer at Pfizer. Early career includes roles at Chiron and serving as a postdoctoral researcher at UC Berkeley, specializing in protein engineering. Educational background includes a postdoctoral degree from the University of California, Berkeley, and earlier studies at Universitat de Barcelona.
This person is not in any teams
This person is not in any offices
venBio
1 followers
venBio invests in promising companies at various stages, from early to late-stage, and from academic startups to spinouts. They tend to lead most of their investments, and they enjoy building syndicates and teams.